Vertex Pharmaceuticals Inc (VRTX) — 分析摘要
Vertex Pharmaceuticals Inc（VRTX）的市值为121.89十亿美元，最近一年的营收同比增长了+8.9%。净利润率为32.9%。当前市盈率为28.1倍。
核心要点
- 营收同比变化+8.9%
- 净利润率32.9%
- 市盈率28.1倍
与PHARMACEUTICAL PREPARATIONS板块的其他公司相比，VRTX的营收增长为+8.9%，市盈率为28.1倍。
Vertex Pharmaceuticals Inc (VRTX)
更新 — ET · 来源 POLYGON
红旗与风险提示无重大红旗
基于最新财报，没有触发重大的信用、利润率或趋势红旗。
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
行业
PHARMACEUTICAL PREPARATIONS
员工人数
6,400
总部
BOSTON, MA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。